Fraxiparine · PIN 09853944 · 9500IU/mL · pre-filled syringe-0.4mL Pk
Limited Use — Reason for Use code 186, 187, 188, 189 requiredOntario PIN; no Health Canada record under this code
StatusLimited Use — Reason for Use code 186, 187, 188, 189 required
Write on scriptLU code 186, 187, 188, 189 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check Health Canada brand searchPrivate plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Nadroparin
Brand(s): Fraxiparine
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
30
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 30, record 10, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fraxiparine · DIN 09853944
Manufacturer: Aspen Pharma Trading Limited; listing date 1999-04-15
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Fraxiparine: Formulary list price $6.8400/unit (unit not stated in source; not the patient's cost)
Ministry pays: $6.8400 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09853944)
Source record
DIN 09853944: Fraxiparine
Raw flags: sec12=Y, sec3=Y
Item: 201200051; group id 258; item number 0500; lccId 00047; manufacturer id ASN
Source form: Pref Syr-0.4mL Pk; strength: 9500IU/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $6.8400; ministry $6.8400
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09853944
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: not checked (no credentials)